Published in Clin Infect Dis on March 16, 2015
Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Med (2016) 1.61
Phenotypically Adapted Mycobacterium tuberculosis Populations from Sputum Are Tolerant to First-Line Drugs. Antimicrob Agents Chemother (2016) 0.81
Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy. BMC Med (2016) 0.80
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis (2016) 0.79
Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary Tuberculosis. CPT Pharmacometrics Syst Pharmacol (2016) 0.78
Multiscale Model of Mycobacterium tuberculosis Infection Maps Metabolite and Gene Perturbations to Granuloma Sterilization Predictions. Infect Immun (2016) 0.75
TST positivity in household contacts of tuberculosis patients: a case-contact study in Malawi. BMC Infect Dis (2017) 0.75
Serial image analysis of Mycobacterium tuberculosis colony growth reveals a persistent subpopulation in sputum during treatment of pulmonary TB. Tuberculosis (Edinb) (2016) 0.75
Assessment of treatment response in tuberculosis. Expert Rev Respir Med (2016) 0.75
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. Clin Infect Dis (2017) 0.75
Genetic determinants of the pharmacokinetic variability of rifampicin in Malawian adults with pulmonary tuberculosis. Antimicrob Agents Chemother (2017) 0.75
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med (2009) 5.78
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (2009) 5.30
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med (2014) 5.23
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis (2008) 3.77
The action of antituberculosis drugs in short-course chemotherapy. Tubercle (1985) 3.69
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov (2013) 3.50
Spectrofluorometric studies of the lipid probe, nile red. J Lipid Res (1985) 3.25
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med (2008) 3.01
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med (2014) 2.42
A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med (2014) 2.39
A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One (2009) 2.15
Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog (2011) 1.99
Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum. Microbiology (2002) 1.97
Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum. Am J Respir Crit Care Med (2009) 1.79
Tuberculosis. Scientific blueprint for tuberculosis drug development. Tuberculosis (Edinb) (2001) 1.68
Targeting persisters for tuberculosis control. Antimicrob Agents Chemother (2012) 1.65
A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis. Thorax (2010) 1.55
Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS (2010) 1.52
Consequences of dichotomization. Pharm Stat (2009) 1.43
The search for new sterilizing anti-tuberculosis drugs. Front Biosci (2004) 1.39
Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One (2011) 1.38
An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One (2013) 1.36
Identification and structural characterization of an unusual mycobacterial monomeromycolyl-diacylglycerol. Mol Microbiol (2005) 1.29
Prospects for advancing tuberculosis control efforts through novel therapies. PLoS Med (2006) 1.27
Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J Clin Microbiol (2010) 1.11
Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob Agents Chemother (2006) 1.10
The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: a retrospective cohort study. Clin Infect Dis (2014) 1.04
The variability of Mycobacterium tuberculosis in patients with cavitary pulmonary tuberculosis in the course of chemotherapy. Tubercle (1987) 1.00
Recent advances in tuberculosis: New drugs and treatment regimens. Curr Respir Med Rev (2013) 0.91
Optimal sampling strategies for early pharmacodynamic measures in tuberculosis. J Antimicrob Chemother (2006) 0.90
Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings. J Clin Microbiol (2012) 0.89
Prediction of delayed treatment response in pulmonary tuberculosis: use of time to positivity values of Bactec cultures. Tuberculosis (Edinb) (2008) 0.84
Simple liquid-chromatographic method for Nile Red quantification in cell culture in spite of photobleaching. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.77
The Role of Human Immunodeficiency Virus-Associated Vasculopathy in the Etiology of Stroke. J Infect Dis (2017) 0.75